BerGenBio Appoints Olav Hellebø as CEO

"BerGenBio is at the forefront of exploring highly selective AXL inhibition as a therapeutic enhancement for the large number of patients with non-squamous non-small cell lung cancer with mutations in the STK11 gene. I am thrilled to join the company and look forward to collaborating with the board and team to advance the candidate drug, bemcentinib, through the next stages of clinical development and to take BerGenBio to the next phase", said Olav Hellebø.

"Mr. Hellebø brings a wealth of experience as a leader in pharmaceutical and biotechnology companies, with a strong track record of success. His extensive expertise in leading biotech companies, raising capital, and securing partnership deals makes him exceptionally well-suited to guide BerGenBio and to execute on our focused strategy to study STK11m NSCLC patients in our on-going Ph1b/2a BGBC016 trial", said Chairman of the Board, Anders Tullgren.

Contacts

Anders Tullgren, Chair of the Board, BerGenBio ASA
[email protected]

Rune Skeie, CFO, BerGenBio ASA
[email protected]

Jan Lilleby, Media Relations, BerGenBio ASA
[email protected]

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bergenbio-asa/r/bergenbio-appoints-olav-hellebo-as-ceo,c4069475

View original content:https://www.prnewswire.co.uk/news-releases/bergenbio-appoints-olav-hellebo-as-ceo-302312066.html